TriangleNCT00364923 · REGISTRY CONDITION SEARCH
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2019-12-19
Primary • Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) Secondary * Determine the safety of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory PTCL * Determine the pharmacokinetic (PK) profile of pralatrexate when administered with vitamin B12 and folic acid supplementation
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Response Rate Per Independent Central Review
Duration of Response Per Independent Central Review
Progression-free Survival Per Independent Central Review
Overall Survival Per Independent Central Review
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Histologically/cytologically confirmed PTCL, using the Revised European American Lymphoma (REAL) World Health Organization (WHO) disease classification: 1. T/Natural Killer (T/NK) cell leukemia/lymphoma 2. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus \[HTLV\] 1+) 3. Angioimmunoblastic T cell lymphoma 4. Blastic Natural Killer (NK) lymphoma (with skin, lymph node, or visceral involvement) 5. Anaplastic large cell lymphoma, primary systemic type 6. PTCL - unspecified 7. T/NK-cell lymphoma - nasal 8. Enteropathy-type intestinal lymphoma 9. Hepatosplenic T cell lymphoma 10. Extranodal peripheral T/NK-cell lymphoma - unspecified 11. Subcutaneous panniculitis T-cell lymphoma 12. Transformed mycosis fungoides * Documented progression of disease after at least 1 prior treatment. Patients may not have received experimental therapy as their only prior therapy. Patient has at least 1 biopsy from initial diagnosis or in the relapsed setting to confirm the diagnosis of PTCL. Patient has recovered from the toxic effects of prior therapy. Patients treated with monoclonal antibody therapy may be enrolled regardless of the time frame of the therapy if they have progression of disease. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. * ≥ 18 years of age. * Adequate hematological, hepatic, and renal function. * Women of childbearing potential must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Patients who are postmenopausal for at least 1 year or are surgically sterilized do not require this test. * Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate. * Patient has given written informed consent. Exclusion Criteria: * Patient has: 1. Precursor T/NK neoplasms, with the exception of blastic NK lymphoma 2. T cell prolymphocytic leukemia (T-PLL) 3. T cell large granular lymphocytic leukemia 4. Mycosis fungoides, other than transformed mycosis fungoides 5. Sézary syndrome 6. Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis * Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease free for greater than or equal to 5 years. * Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure Guidelines. * Uncontrolled hypertension. * Human immunodeficiency virus (HIV)-positive diagnosis and is receiving combination anti-retroviral therapy. * Patient has, or history of, brain metastases or central nervous system (CNS) disease. * Patient has undergone an allogeneic stem cell transplant. * Patient has relapsed less than 75 days from time of an autologous stem cell transplant. * Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to receive protocol treatment. * Major surgery within 2 weeks of study entry. * Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study. * Receipt of corticosteroids within 7 days of study treatment, unless patient has been taking a continuous dose of no more than 10 mg/day of prednisone for at least 1 month. * Use of any investigational drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the course of the study. * Previous exposure to pralatrexate.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- interventions
- description
- Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
- name
- Pralatrexate Injection
- other Names
- FOLOTYN
- Pralatrexate
- Pralatrexate Solution for Infusion
- (RS)-10-propargyl-10-deazaaminopterin
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 115
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Patient response to treatment was determined by independent central review using International Workshop Criteria (IWC). Results present the best overall response. The initial response assessment was scheduled at week 7 (prior to Cycle 2) and then prior to every even-numbered cycle (every 14 weeks) for up to two years after first dose.
- measure
- Response Rate Per Independent Central Review
- time Frame
- Response was assessed at 7 weeks (prior to Cycle 2) and then prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose
- secondary Outcomes
- description
- Calculated only for those pts with an objective response. Pts receiving subsequent therapy (including transplant) before progressive disease (PD) was documented were censored at date of last response assessment obtained prior to subsequent therapy, with a note indicating censoring occurrence \& reason. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last evaluable assessment of response. Pts who withdrew from treatment prior to PD or initiation of subsequent therapy without withdrawing consent were followed for disease status when possible.
- measure
- Duration of Response Per Independent Central Review
- time Frame
- Measured from the first day of documented response, assessed at prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose
- description
- Patients (pts) with subsequent therapy prior to PD were censored at date of last response assessment prior to subsequent therapy. Pts who were alive without PD were censored at the date of last assessment of first dose. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last disease assessment or treatment day 1. Pts who withdrew consent from treatment prior to PD without withdrawing consent for follow-up were followed for disease status \& survival. Pts who did not have response assessments after baseline were censored at treatment day 1.
- measure
- Progression-free Survival Per Independent Central Review
- time Frame
- Calculated as the number of days from treatment day 1 to the date of disease progression or death, regardless of cause for up to 2 years after initial dose
- description
- Calculated as date of death - date of enrollment +1, estimated using the product-limit estimator. Pts who had not died (no record of death) or were lost to follow-up were censored at the date of last contact. Pts who withdrew consent to participate in the study including consent to be followed, were censored on the date of withdrawal. Pts who withdrew from treatment without withdrawing consent were followed for survival status whenever possible.
- measure
- Overall Survival Per Independent Central Review
- time Frame
- Assessed every 14 weeks while on treatment, and after disease progression no less frequently than every 6 months for up to 2 years after first dose.
Full study description
- brief Summary
- Primary • Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) Secondary * Determine the safety of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory PTCL * Determine the pharmacokinetic (PK) profile of pralatrexate when administered with vitamin B12 and folic acid supplementation
- detailed Description
- This is a Phase 2, single arm, non-randomized, open-label, multi-center study designed to evaluate the safety and effectiveness of pralatrexate when administered with vitamin B12 and folic acid supplementation to patients with relapsed or refractory PTCL. Pralatrexate will be given over 3-5 minutes intravenously (IV), which means through a vein. If pralatrexate is tolerated well, the patient will receive IV injections of pralatrexate every week for 6 weeks, followed by 1 week without receiving pralatrexate. These 7 week cycles will be repeated depending on response and tolerability.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-6261e7e2c55d0d7cb3cd
- requested nct id
- NCT00364923
- primary nct id
- NCT00364923
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- payload sha256
- ebdfd2c7932dd041cf1207a1b8cfdd6ffbd170b751ff4d02c7c6506923bc79d6
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-6261e7e2c55d0d7cb3cd
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00364923
- occurrences
- context exact
- NCT00364923
- end
- 11
- exact text
- NCT00364923
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Peripheral T-Cell Non-Hodgkin Lymphoma
- query disease state id
- ds-peripheral-t-cell-non-hodgkin-lymphoma
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- source json pointer
- /studies/72/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 44ae2590eea370404488a94d0239ec4da8804d3610124013a678b21cfe62213b
Preserved source evidence · Not medical advice